Trevi Therapeutics Obtains $10,000,000 Series A Funding Round

  • Feed Type
  • Date
  • Company Name
    Trevi Therapeutics
  • Mailing Address
    52 Charter Ridge Road New Haven, CT 06511
  • Company Description
    Trevi Therapeutics, Inc. is a drug development company founded in 2011 focused on developing T111 for the severe chronic itching condition known as pruritus. Pruritus is manifested in various dermatological, metabolic, hematologic and neuronal conditions. The Company is pursuing uremic pruritus as the lead indication. Uremic pruritus is a persistent and debilitating itching in patients on dialysis that has been linked to increased mortality. T111 is an oral extended release opioid with a unique dual agonist/antagonist mechanism of action, which has been shown in both animal and human clinical studies as being effective in pruritus.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    With the proceeds from the Series A investment, Trevi intends to advance T111, an oral extended release opioid with a unique agonist/antagonist mechanism of action, into clinical development for the treatment of uremic pruritus.
  • M&A Terms
  • Venture Investor
    TPG Biotech

Trending on Xconomy